Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Elongating Prodrug Half Life Using an Albumin Binding Probe
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID: 1555
Most polypeptide drugs, in particular non-glycosylated proteins of molecular mass less than 50 kDa, are short-lived species in vivo having circulatory half lives of 5-20 min. Drug association...
Contact
Participants
You
Email me a copy of this message
Introduction/Background

Most polypeptide drugs, in particular non-glycosylated proteins of molecular mass less than 50 kDa, are short-lived species in vivo having circulatory half lives of 5-20 min. Drug association with endogenous albumin may be suitable for designing an approach to protract the action in vivo of, potentially, any short-lived peptide/protein drug. In doing so two principal obstacles must be overcome: (1) following its conjugation, the probe introduced into a peptide or a protein should have sufficient affinity to albumin to manifest prolonged action in vivo, and (2) in case such covalent introduction results in an inactive product, the latter should be capable to undergo slow reactivation at physiological conditions.

Aims/Hypothesis

We aim to develop an albumin binding probe for extending the lifetime of drugs.

Results

Since albumin is long-lived in vivo, drugs and endogenous substances that tightly associate with it have lower clearance rates than that of the unbound substances, and exhibit prolonged lifetime profiles in vivo. The present invention is based on a concept according to which a long chain fatty acid (LCFA) like albumin-binding compound is covalently linked to a short-lived amino-containing drug to form a non-covalent drug conjugate capable of associating with albumin in vivo, ie, a long-lived prodrug that gradually releases the pharmacologically active constituent. This approach has been successfully implemented with several drugs (eg, insulin, exendin and gentamicin).

Conclusion

The present invention relates to engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions.

Relevance/Opportunity

Turning short-lived amino-containing drugs into inactive reactivable prodrugs having prolonged lifetime profiles in vivo. Please enquire quoting reference no. 1555 regarding licensing or codevelopment partnerships.
FEATURED
Last Updated May 2015
Technology Type PLATFORM
Phase of Development CLINICAL TRIALS
CORPORATION